Pure Global
NCT05949944

Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma

Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma：a Single-Arm, Open Lable， Multicenter Clinical Trial（LINCH Study）
Sun Yat-sen University·Phase 1/2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
Linperlisib in combination with CHOP
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sun Yat-sen University
Timeline & enrollment
Phase
Phase 1/2
Start date
Aug 01, 2023
End date
Dec 01, 2026
Enrollment
48 participants
Primary outcome

Dose-limiting toxicity (DLT, Phase Ib),Complete remission rate (CR rate) based on the 2014 Lugano evaluation criteria (Phase II)

Summary

This phase Ib/II, single arm, open label, multicenter study is conducted to evaluate the
 efficacy and safety of linperlisib in combination with CHOP for newly diagnosed PTCL
 patients, and explore the reasonable dosage of linperlisib when combined with CHOP regimen.

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05949944
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05949944 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Sun Yat-sen University and is currently Not yet recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.